DGIdb - VINCRISTINE Drug Record

VINCRISTINE chembl:CHEMBL90555 ApprovedAntineoplasticImmunotherapy

Alternate Names:

VINCRISTINE
LEUROCRISTINE
NSC-67574
LEUROCRISTINE SULFATE
VINCRISTIN
ONCOVIN®
22-OXOVINCALEUKOBLASTINE
VINCRISTINUM
KYOCRISTINE
22-OXOVINCALEUKOBLASTIN
VINCRISTINA
pubchem.compound:5978
chemidplus:57-22-7
rxcui:11202
chembl:CHEMBL90555
drugbank:00541

Drug Info:

FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	antineoplastic agent
Year of Approval	1963
Drug Class	antineoplastic agents

(7 More Sources)

Publications:

Kalra S et al., 2018, Association of CYP2C192 and ALDH1A11/*2 variants with disease outcome in breast cancer patients: results of a global screening array., Eur J Clin Pharmacol
Rossi D et al., 2009, Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21., Leukemia
Wick et al., 2004, Chemotherapy-induced cell death in primary cerebellar granule neurons but not in astrocytes: in vitro paradigm of differential neurotoxicity., J. Neurochem.
Kawaratani Y et al., 2011, New microtubule polymerization inhibitors comprising a nitrooxymethylphenyl group., Bioorg Med Chem
Cheng YY et al., 2013, Design, synthesis, and mechanism of action of 2-(3-hydroxy-5-methoxyphenyl)-6-pyrrolidinylquinolin-4-one as a potent anticancer lead., Bioorg Med Chem Lett
Gasparotto V et al., 2006, Synthesis and biological activity of 7-phenyl-6,9-dihydro-3H-pyrrolo[3,2-f]quinolin-9-ones: a new class of antimitotic agents devoid of aromatase activity., J Med Chem
Gutierrez-Camino A et al., 2017, PNPLA3 rs738409 and Hepatotoxicity in Children With B-cell Acute Lymphoblastic Leukemia: A Validation Study in a Spanish Cohort., Clin Pharmacol Ther
López-López E et al., 2014, Pharmacogenetics of microRNAs and microRNAs biogenesis machinery in pediatric acute lymphoblastic leukemia., PLoS One
Vellon et al., 2007, Up-regulation of alphavbeta3 integrin expression is a novel molecular response to chemotherapy-induced cell damage in a heregulin-dependent manner., Differentiation
Butrym A et al., 2016, Dual role of the CXCL12 polymorphism in patients with chronic lymphocytic leukemia., HLA
Kurtzberg et al., 2009, Bone marrow CFU-GM and human tumor xenograft efficacy of three tubulin binding agents., Cancer Chemother. Pharmacol.
Gan et al., 2010, Microtubule dynamics, mitotic arrest, and apoptosis: drug-induced differential effects of betaIII-tubulin., Mol. Cancer Ther.
Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
Karol SE et al., 2016, Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia., Blood
Perez-Andreu V et al., 2013, Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse., Nat Genet
Wiestler et al., 2013, ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis., Acta Neuropathol.
Yasui et al., 2010, Live cell imaging of micronucleus formation and development., Mutat. Res.
Vilpo et al., 2000, Selective toxicity of vincristine against chronic lymphocytic leukemia cells in vitro., Eur. J. Haematol.
Sano, 2001, Radicicol and geldanamycin prevent neurotoxic effects of anti-cancer drugs on cultured embryonic sensory neurons., Neuropharmacology
Kobrinsky et al., 2005, Successful treatment of doxorubicin and cisplatin resistant hepatoblastoma in a child with Beckwith-Wiedemann syndrome with high dose acetaminophen and N-acetylcysteine rescue., Pediatr Blood Cancer
Pui et al., 1985, Altered von Willebrand factor molecule in children with thrombosis following asparaginase-prednisone-vincristine therapy for leukemia., J. Clin. Oncol.
Schinkel et al., 1991, Characterization of the human MDR3 P-glycoprotein and its recognition by P-glycoprotein-specific monoclonal antibodies., Cancer Res.
Ahn et al., 1997, Oxidations of vincristine catalyzed by peroxidase and ceruloplasmin., J. Nat. Prod.
Caronia D et al., 2011, Effect of ABCB1 and ABCC3 polymorphisms on osteosarcoma survival after chemotherapy: a pharmacogenetic study., PLoS One
Jordheim LP et al., 2015, Single nucleotide polymorphisms in ABCB1 and CBR1 can predict toxicity to R-CHOP type regimens in patients with diffuse non-Hodgkin lymphoma., Haematologica
Gregers J et al., 2015, Polymorphisms in the ABCB1 gene and effect on outcome and toxicity in childhood acute lymphoblastic leukemia., Pharmacogenomics J
Maggini V et al., 2008, MDR1 diplotypes as prognostic markers in multiple myeloma., Pharmacogenet Genomics
Lopez-Lopez E et al., 2016, Vincristine pharmacokinetics pathway and neurotoxicity during early phases of treatment in pediatric acute lymphoblastic leukemia., Pharmacogenomics
Filipits et al., 2003, Low p27Kip1 expression is an independent adverse prognostic factor in patients with multiple myeloma., Clin. Cancer Res.
Andreani A et al., 2008, Antitumor activity of new substituted 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-indolinones and 3-(5-imidazo[2,1-b]thiadiazolylmethylene)-2-indolinones: selectivity against colon tumor cells and effect on cell cycle-related events., J Med Chem
Kaneko et al., 2002, Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification., J. Pediatr. Hematol. Oncol.
Klauber et al., 1997, Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol., Cancer Res.
McPherson et al., Selective sensitization of adriamycin-resistant P388 murine leukemia cells to antineoplastic agents following transfection with human DNA topoisomerase II alpha., Anticancer Res.
Fujiwara et al., 2007, Blockade of the phosphatidylinositol-3-kinase-Akt signaling pathway enhances the induction of apoptosis by microtubule-destabilizing agents in tumor cells in which the pathway is constitutively activated., Mol. Cancer Ther.
Shingu et al., 2003, Synergistic augmentation of antimicrotubule agent-induced cytotoxicity by a phosphoinositide 3-kinase inhibitor in human malignant glioma cells., Cancer Res.
Tsukamoto et al., 1989, Effect of colchicine and vincristine on DNA synthesis in regenerating rat liver., Biochim. Biophys. Acta
Twentyman et al., 1990, Chemosensitisation by verapamil and cyclosporin A in mouse tumour cells expressing different levels of P-glycoprotein and CP22 (sorcin)., Br. J. Cancer
Moriyama T et al., 2015, Inherited genetic variation in childhood acute lymphoblastic leukemia., Blood

VINCRISTINE CEP72

Interaction Score: 2.2

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25999454

Sources:
PharmGKB
VINCRISTINE RALBP1

Interaction Score: 1.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27180762

Sources:
PharmGKB
VINCRISTINE ACTG1

Interaction Score: 1.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
VINCRISTINE CAPG

Interaction Score: 1.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
VINCRISTINE ODC1

Interaction Score: 0.73

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19006285

Sources:
DTC
VINCRISTINE SRI

Interaction Score: 0.55

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
1975203

Sources:
NCI
VINCRISTINE GSTA1

Interaction Score: 0.37

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29938344 19448608

Sources:
PharmGKB
VINCRISTINE PNPLA3

Interaction Score: 0.37

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28744905

Sources:
PharmGKB
VINCRISTINE ABCB4

Interaction Score: 0.31

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
1673638

Sources:
NCI
VINCRISTINE CXCL12

Interaction Score: 0.31

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27173875

Sources:
PharmGKB
VINCRISTINE DROSHA

Interaction Score: 0.31

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24614921

Sources:
PharmGKB
VINCRISTINE ABCC10

Interaction Score: 0.27

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
VINCRISTINE MYCN

Interaction Score: 0.24

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12439032

Sources:
NCI
VINCRISTINE ATRX

Interaction Score: 0.24

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23904111

Sources:
CIViC
VINCRISTINE BMP7

Interaction Score: 0.22

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26590194

Sources:
PharmGKB
VINCRISTINE LINC00251

Interaction Score: 0.22

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26590194

Sources:
PharmGKB
VINCRISTINE DOK5

Interaction Score: 0.22

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26590194

Sources:
PharmGKB
VINCRISTINE TUBA4A

Interaction Score: 0.21

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name vincristine sulfate liposomes injection, Onco TCS,Marqibo

Novel drug target Established target

PMIDs:
20442307 20691709 11168494 21664138 23916255 16539377

Sources:
DTC TdgClinicalTrial
VINCRISTINE TUBB4A

Interaction Score: 0.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21664138 23916255 16539377

Sources:
DTC
VINCRISTINE TUBA3C

Interaction Score: 0.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21664138 23916255 16539377

Sources:
DTC
VINCRISTINE TUBB

Interaction Score: 0.21

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? True

PMIDs:
19277662 20442307 17016423 17139284 21664138 23916255 16539377

Sources:
DTC GuideToPharmacology TTD
VINCRISTINE CDKN1B

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12576455

Sources:
NCI
VINCRISTINE AFP

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15770640

Sources:
NCI
VINCRISTINE BCR

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

Fusion protein BCR:ABL1

PMIDs:
None found

Sources:
PharmGKB FDA
VINCRISTINE GATA3

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24141364

Sources:
PharmGKB
VINCRISTINE TUBB2A

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name vincristine sulfate liposomes injection, Onco TCS,Marqibo

Novel drug target Established target

PMIDs:
21664138 23916255 16539377

Sources:
DTC TdgClinicalTrial TEND
VINCRISTINE CP

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9392881

Sources:
NCI
VINCRISTINE VWF

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
3875694

Sources:
NCI
VINCRISTINE NTF3

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11378165

Sources:
NCI
VINCRISTINE TUBB6

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16539377 21664138 23916255

Sources:
DTC
VINCRISTINE TUBA1B

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21664138 23916255 16539377

Sources:
DTC
VINCRISTINE TUBA3D

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21664138 23916255 16539377

Sources:
DTC
VINCRISTINE TUBA1C

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21664138 23916255 16539377

Sources:
DTC
VINCRISTINE TUBA3E

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21664138 23916255 16539377

Sources:
DTC
VINCRISTINE TUBB8

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21664138 23916255 16539377

Sources:
DTC
VINCRISTINE TUBB2B

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21664138 23916255 16539377

Sources:
DTC
VINCRISTINE TUBA1A

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21664138 23916255 16539377

Sources:
DTC
VINCRISTINE TUBB3

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21664138 23916255 16539377

Sources:
DTC
VINCRISTINE FGF2

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8988045

Sources:
NCI
VINCRISTINE TUBB4B

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21664138 23916255 16539377

Sources:
DTC
VINCRISTINE NRG1

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17999741

Sources:
NCI
VINCRISTINE ABCC3

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22016816

Sources:
PharmGKB
VINCRISTINE TUBB1

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21664138 23916255 16539377

Sources:
DTC
VINCRISTINE TYMS

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
2804079

Sources:
NCI
VINCRISTINE BDNF

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15569250

Sources:
NCI
VINCRISTINE PIK3CG

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17363506 12874004

Sources:
NCI
VINCRISTINE ABL1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

Fusion protein BCR:ABL1

PMIDs:
None found

Sources:
PharmGKB FDA
VINCRISTINE ABCB1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29938344 25637052 25582575 22016816 18408561

Sources:
PharmGKB
VINCRISTINE TOP2A

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9494516

Sources:
NCI
VINCRISTINE BCL2

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
VINCRISTINE ABCC1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
VINCRISTINE ABCC2

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
VINCRISTINE PIK3CA

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12874004

Sources:
NCI
VINCRISTINE CYP3A5

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
VINCRISTINE NR1I2

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
VINCRISTINE SMAD3

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
VINCRISTINE GMNN

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
VINCRISTINE AR

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

TEND: VINCRISTINE
- Version: 01-August-2011
Alternate Names:

VINCRISTINE Primary Drug Name

Drug Info:

Drug Class antineoplastic agents

Year of Approval 1963

Publications:
TdgClinicalTrial: VINCRISTINE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small Molecule

FDA Approval approved

Publications:

DTC: VINCRISTINE

Version: 02-September-2020

Alternate Names:

CHEMBL90555 ChEMBL Drug ID

Drug Info:

Publications:

Gasparotto V et al., 2006, Synthesis and biological activity of 7-phenyl-6,9-dihydro-3H-pyrrolo[3,2-f]quinolin-9-ones: a new class of antimitotic agents devoid of aromatase activity., J Med Chem

Kawaratani Y et al., 2011, New microtubule polymerization inhibitors comprising a nitrooxymethylphenyl group., Bioorg Med Chem

Cheng YY et al., 2013, Design, synthesis, and mechanism of action of 2-(3-hydroxy-5-methoxyphenyl)-6-pyrrolidinylquinolin-4-one as a potent anticancer lead., Bioorg Med Chem Lett

NCI: VINCRISTINE

Version: 14-September-2017

Alternate Names:

C933 NCI drug code

Drug Info:

Publications:

Tsukamoto et al., 1989, Effect of colchicine and vincristine on DNA synthesis in regenerating rat liver., Biochim. Biophys. Acta

Ahn et al., 1997, Oxidations of vincristine catalyzed by peroxidase and ceruloplasmin., J. Nat. Prod.

Kaneko et al., 2002, Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification., J. Pediatr. Hematol. Oncol.

PharmGKB: vincristine

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Kalra S et al., 2018, Association of CYP2C192 and ALDH1A11/*2 variants with disease outcome in breast cancer patients: results of a global screening array., Eur J Clin Pharmacol

Rossi D et al., 2009, Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21., Leukemia

Karol SE et al., 2016, Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia., Blood

CIViC: VINCRISTINE
- Version: 14-September-2020
Alternate Names:

Drug Info:

Publications:

Wiestler et al., 2013, ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis., Acta Neuropathol.
TTD: Vincristine
- Version: 2020.06.01
Alternate Names:

D09QVV TTD Drug ID

Drug Info:

Publications:
GuideToPharmacology: 178103391
- Version: 29-September-2020
Alternate Names:

VINCRISTINE GuideToPharmacology Ligand Name

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL90555
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
FDA: Vincristine
- Version: 04-September-2020
Alternate Names:

Drug Info:

Publications:
MyCancerGenomeClinicalTrial: VINCRISTINE
- Version: 30-February-2014
Alternate Names:

Drug Info:

Publications:

Trial Name	vincristine sulfate liposomes injection, Onco TCS,Marqibo
Novel drug target	Established target

Specific Action of the Ligand	Inhibition
Endogenous Drug?	False
Direct Interaction?	True

VINCRISTINE Drug Record

VINCRISTINE chembl:CHEMBL90555 ApprovedAntineoplasticImmunotherapy

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25999454

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27180762

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 19006285

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 1975203

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29938344 19448608

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28744905

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 1673638

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27173875

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24614921

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12439032

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23904111

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26590194

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26590194

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26590194

Sources: PharmGKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name vincristine sulfate liposomes injection, Onco TCS,Marqibo Novel drug target Established target

PMIDs: 20442307 20691709 11168494 21664138 23916255 16539377

Sources: DTC TdgClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21664138 23916255 16539377

Interaction Types & Directionality:

n/a

PMIDs:
25999454

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
27180762

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
19006285

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
1975203

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
29938344 19448608

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
28744905

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
1673638

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
27173875

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
24614921

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
12439032

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
23904111

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
26590194

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
26590194

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
26590194

Sources:
PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name vincristine sulfate liposomes injection, Onco TCS,Marqibo

Novel drug target Established target

PMIDs:
20442307 20691709 11168494 21664138 23916255 16539377

Sources:
DTC TdgClinicalTrial

Interaction Types & Directionality:

n/a

PMIDs:
21664138 23916255 16539377

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
21664138 23916255 16539377

Sources:
DTC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? True

PMIDs:
19277662 20442307 17016423 17139284 21664138 23916255 16539377

Sources:
DTC GuideToPharmacology TTD

Interaction Types & Directionality:

n/a

PMIDs:
12576455

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
15770640

Sources:
NCI

Interaction Types & Directionality:

n/a

Interaction Info:

Fusion protein BCR:ABL1

PMIDs:
None found

Sources:
PharmGKB FDA

Interaction Types & Directionality:

n/a

PMIDs:
24141364

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name vincristine sulfate liposomes injection, Onco TCS,Marqibo

Novel drug target Established target